Aarti Pharmalabs Limited has commissioned a new state-of-the-art manufacturing block at its Tarapur Unit 5 facility in Maharashtra, significantly enhancing its production capabilities for Xanthine derivatives. The expansion marks a major milestone in the company’s growth strategy and reinforces its position as one of the world’s leading manufacturers in this specialty pharmaceutical segment.
Located at MIDC, Tarapur (Plot No. L-28/29/99), the newly inaugurated manufacturing block has received all the statutory approvals and regulatory clearances required to commence operations. The facility adds 3,600 tonnes per annum (TPA) of production capacity for Xanthine derivatives, taking the company’s total installed capacity to 9,600 TPA. With this expansion, Aarti Pharmalabs is now among the top three global manufacturers of Xanthine derivatives, strengthening its ability to serve customers across regulated and emerging markets.
The new facility has been designed to support rising global demand while delivering high standards of quality, operational efficiency and manufacturing excellence. Trial production has already commenced, and the company plans to progressively ramp up operations over the coming quarters to achieve optimum capacity utilisation.
The inauguration ceremony was attended by the company’s senior leadership team along with employees and project teams who played a key role in developing the facility. The commissioning reflects Aarti Pharmalabs’ continued focus on expanding its manufacturing footprint and building capabilities that support long-term customer partnerships.
Commenting on the development, Rashesh Gogri, Chairman, Aarti Pharmalabs Limited, said, “The commissioning of this additional manufacturing block marks a significant milestone in our growth journey. It substantially enhances our production capabilities and strengthens our ability to meet the evolving requirements of our business partners across global markets. Trial production has already begun, and we will steadily scale up operations over the next few quarters to maximise the facility’s potential. This investment reflects our long-term commitment to expanding capacity, improving operational excellence and supporting the future growth of our customers.”
The expanded manufacturing capacity is expected to improve supply reliability, increase production flexibility and enable the company to cater to larger customer requirements in the pharmaceutical and nutraceutical sectors. The investment also supports Aarti Pharmalabs’ strategy of strengthening its presence in high-value specialty products while maintaining a strong focus on quality, compliance and sustainable growth.
Aarti Pharmalabs has established itself as a leading global manufacturer of pharmaceutical and nutraceutical ingredients, serving customers through innovation-driven manufacturing and advanced process capabilities. The company provides comprehensive Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services for small-molecule drug substances, supporting both clinical and commercial programmes for innovator pharmaceutical companies.
Its specialised manufacturing infrastructure includes dedicated facilities for high-potency active pharmaceutical ingredients (HPAPIs), corticosteroids, cytotoxic compounds and oncology products. Alongside its CDMO business, the company also manufactures generic active pharmaceutical ingredients (APIs), intermediates and Xanthine derivatives, supplying customers across regulated international markets.
